Biologics Development Solutions for Companion Animal Therapeutics
Product Description
Canton Biologics
-
Country/Region:Hong Kong
-
Founded:2016
-
On CPHI since:2026
-
Employees:250 - 499
Company types
Categories
Specifications
Canton Biologics
-
Country/Region:Hong Kong
-
Founded:2016
-
On CPHI since:2026
-
Employees:250 - 499
Company types
More Products from Canton Biologics (5)
-
Product Biomedical and Healthcare Recombinant Protein Solutions
Combines molecular engineering, host cell optimisation, expression system development, and process optimisation to address complex protein structures. The IgMax® platform enables production of pentameric IgM at high expression levels, with near‑complete pentamer assembly and excellent purity after downstre... -
Product Innovative Drug Solutions for Difficult‑to‑Express and Complex Proteins
Integrated development and manufacturing solutions combining molecular engineering, vector optimization, host cell engineering, and customized process development. The platform delivers high titers for mAb production, and DTEasy™ strategies have demonstrated significant yield improvements across various di... -
Product Integrated Biosimilar CMC Solutions – from Development to Commercial Manufacturing
End‑to‑end biosimilar development from cell line construction to PPQ and commercial batches. The integrated platform enables a fast development timeline, supports global GMP requirements, and offers competitive cost of goods. Includes DS/DP manufacturing, analytical testing, quality support, and technology... -
Product Integrated CMC Solutions for Advanced Therapies
Customised CMC development and manufacturing for a broad range of advanced biologic modalities. Services include process development, analytical characterisation, scale‑up, and GMP manufacturing, tailored to the characteristics and development stage of each modality.
-
Product Recombinant Antigen and Vaccine Solutions for Livestock & Poultry
Combines advanced expression technologies with optimised vectors, cell culture processes, and downstream purification for high‑productivity and cost‑efficient manufacturing. Multimerisation and nanoparticle platforms enable the design of defined antigen structures in various multimeric forms, supporting ne...




